Arbutus Biopharma swings to Q3 net income of $59.12 million
ABUS•Arbutus Biopharma reported third-quarter 2026 net income of $59.12 million, compared with a loss a year earlier, while revenue fell 43% to $299,000. It had $337.49 million in cash, cash equivalents and marketable securities at September 30, and an October tender offer returned $230 million to shareholders.
1. Quarterly results
Arbutus Biopharma swung to third-quarter 2026 net income of $59.12 million from a year-earlier loss. Revenue fell 43% year over year to $299,000, primarily because of lower license royalty revenue. Cash, cash equivalents and marketable securities totaled $337.49 million at September 30; an October tender offer returned $230 million to shareholders.
2. Legal and clinical updates
Arbutus and Genevant expanded patent enforcement against Pfizer and BioNTech with new lawsuits in Japan and an additional patent claim in Canada. The FDA lifted the clinical hold on AB-101 in October, allowing additional U.S. clinical development.
